Готові списки джерел за темами / Anticoagulant antivitamine K

Добірка наукової літератури з теми "Anticoagulant antivitamine K"

Автор: Grafiati
Опубліковано: 18 травня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Anticoagulant antivitamine K".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Anticoagulant antivitamine K"

1

Mahwish, Nayesha, Laxminarayana Kurady Bairy, and Sureshkumar Srinivasamurthy. "Antivitamins: A Silver Lining in the Era of Antimicrobial Resistance." Journal of Pharmacology and Pharmacotherapeutics 13, no. 1 (March 2022): 5–13. http://dx.doi.org/10.1177/0976500x221080378.

Повний текст джерела
Анотація:
Antivitamins are compounds that negate the biological effects of vitamins. They have been successfully exploited for the development of various classes of drugs. In the early 19th century, the antifolate prontosil was developed for the treatment of puerperal fever. Since then, numerous other antifolates have been used to treat a wide range of infections. Antifolates, such as methotrexate, are potent anticancer agents and antivitamin K, such as warfarin, are used as anticoagulants. Despite several years of research, most antivitamin-based drugs are limited to vitamin K and B9, and the development of antagonists for other vitamins is still in the nascent stage. In the era of antimicrobial resistance, antivitamins can be considered as a promising alternative to develop newer antimicrobials and are worth exploring further. This review discusses key antivitamins at different stages of development which have potential utility as antibiotic drug candidates. The summary of studies of antivitamins in clinical development is also narrated.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Blin, P., C. Dureau-Pournin, R. Lassalle, A. Abouelfath, K. Le Lay, G. de Pouvourville, C. Droz-Perroteau, and N. Moore. "Ressources consommées et coûts associés des patients traités par anticoagulant oral direct ou antivitamine K dans la fibrillation auriculaire non valvulaire." Revue d'Épidémiologie et de Santé Publique 64 (December 2016): S309—S310. http://dx.doi.org/10.1016/j.respe.2016.10.051.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Foletti, Mauro, Thomas Schmutz, Yvan Fleury, Jean-Luc Magnin, Christophe Le Terrier, and Youcef Guechi. "Bleeding on oral anticoagulants: overview of reversal strategies." Swiss Medical Weekly 153, no. 2 (February 20, 2023): 40036. http://dx.doi.org/10.57187/smw.2023.40036.

Повний текст джерела
Анотація:
Oral anticoagulants (antivitamin K, direct oral anticoagulants) are routinely prescribed for the prevention or treatment of thromboembolic events, and many patients are now on long-term anticoagulant therapy. However, this complicates the management of urgent surgical conditions or major bleeding. Various strategies have been developed to reverse the anticoagulant effect and this narrative review provides an overview of the wide range of therapies currently available.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Bavozet, Florent, and Isabelle Mahé. "Relais d’un traitement anticoagulant oral par antivitamine K en ambulatoire dans le cadre d’un acte invasif ou de chirurgie programmée. Enquête de pratique auprès de médecins généralistes." La Presse Médicale 43, no. 7-8 (July 2014): e221-e231. http://dx.doi.org/10.1016/j.lpm.2013.12.016.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

DIACONU, Camelia, Giorgiana DEDIU, Mădălina ILIE, and Mihaela Adela IANCU. "Treatment with new oral anticoagulants in the family medicine practice." Romanian Journal of Medical Practice 10, no. 4 (December 31, 2015): 329–32. http://dx.doi.org/10.37897/rjmp.2015.4.4.

Повний текст джерела
Анотація:
Vitamin K antagonists represented for more than 50 years the only oral anticoagulant treatment option, though encumbered by numerous food and drug interactions, with direct impact on the safety and efficacy of this treatment. The frequent complications of anticoagulant treatment with vitamin K antagonists led to the need for the emergence of new oral anticoagulants (NOAC). The main NOACs used today are dabigatran, rivaroxaban and apixaban. NOAC have a number of advantages over antivitamin K anticoagulants: fewer drug interactions, no food interactions, rapid onset of the anticoagulant action, rapid clearance, no need for INR monitoring. NOAC therapy must be individualized according to patient age, comorbidities and medical history, renal function, concomitant medications. Given that clinical experience with NOAC is still limited in practice, physicians (including family physicians) must monitor these patients and need to pay attention and report any side effects.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Bokarev, Igor N. "Anticoagulants today." Clinical Medicine (Russian Journal) 94, no. 1 (February 19, 2016): 5–9. http://dx.doi.org/10.18821/0023-2149-2016-94-1-5-9.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Poenou, Géraldine, Marco Heestermans, Ludovic Lafaie, Sandrine Accassat, Nathalie Moulin, Alexandre Rodière, Bastien Petit, Cécile Duvillard, Patrick Mismetti, and Laurent Bertoletti. "Inhibition of Factor XI: A New Era in the Treatment of Venous Thromboembolism in Cancer Patients?" International Journal of Molecular Sciences 24, no. 19 (September 22, 2023): 14433. http://dx.doi.org/10.3390/ijms241914433.

Повний текст джерела
Анотація:
Direct oral anticoagulants against activated factor X and thrombin were the last milestone in thrombosis treatment. Step by step, they replaced antivitamin K and heparins in most of their therapeutic indications. As effective as the previous anticoagulant, the decreased but persistent risk of bleeding while using direct oral anticoagulants has created space for new therapeutics aiming to provide the same efficacy with better safety. On this basis, drug targeting factor XI emerged as an option. In particular, cancer patients might be one of the populations that will most benefit from this technical advance. In this review, after a brief presentation of the different factor IX inhibitors, we explore the potential benefit of this new treatment for cancer patients.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Anguas-Gracia, Ana, Ana Belén Subirón-Valera, Beatriz Rodríguez-Roca, Ángel Gasch-Gallén, Isabel Antón-Solanas, and Fernando Urcola-Pardo. "Sense of Coherence and Quality of Life in Patients Treated with Antivitamin K Oral Anticoagulants: A Cross-Sectional Study." International Journal of Environmental Research and Public Health 18, no. 4 (February 9, 2021): 1668. http://dx.doi.org/10.3390/ijerph18041668.

Повний текст джерела
Анотація:
The aim of this study was to analyze the correlation between the participants’ self-reported quality of life and their sense of coherence in a sample (n = 85) of patients on treatment with oral antivitamin K anticoagulants. A cross-sectional design was used. The measurement instruments included a questionnaire on sociodemographic variables, the Spanish version of the Abbreviated World Health Organization Quality of Life questionnaire (WHOQOL-BREF), an oral-anticoagulant-treatment-specific quality-of-life questionnaire, and the sense-of-coherence (SOC) scale. We analyzed the correlations between the participants’ characteristics and the results from the quality-of-life and SOC scales. Age, level of education, employment status, living arrangement, and treatment length were the determinants of the quality of life in people treated with oral anticoagulants. We found a significant association between the four domains of the WHOQOL-BREF questionnaire and general treatment satisfaction (p < 0.01); no significant correlations were found between the SOC subscales and the oral-anticoagulant-treatment-specific quality of life in our sample. Women had a worse level of self-management than men. Nursing interventions should be tailored to the needs of the populations on treatment with oral anticoagulants in order to facilitate a higher level of self-management.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Gheorghe, Gabriela Silvia, Andreea Simona Hodorogea, Andrei Cristian Dan Gheorghe, Dragoș Emanuel Popa, Simona Vulpe, Cristina Georgescu, Ruxandra Bănică, et al. "Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era." Healthcare 10, no. 7 (July 18, 2022): 1333. http://dx.doi.org/10.3390/healthcare10071333.

Повний текст джерела
Анотація:
Background. Patients with nonvalvular atrial fibrillation (NVAF) have five times higher risk of stroke than the general population. Anticoagulation (ACO) in NVAF is a class I indication after assessing the CHA2DS2-VASc and HAS-BLED scores. However, in the real world, NVAF patients receive less ACO than needed due to patients’ comorbidities that can be assessed by the Charlson comorbidity index (CCI). The use of non-antivitamin K anticoagulants (NOAC) has improved the decision to anticoagulate. Objective. We analyzed the factors influencing the ACO prescribing decision in NVAF patients in the real world and the changes induced by the introduction of NOAC. Method. We carried out an observational retrospective cross-sectional study that included consecutive patients with permanent NVAF and CHA2DS2-VASc ≥ 2, admitted to a community hospital between 2010–2011 (group 1, 286 patients), when only vitamin K antagonists (VKA) were used, and 2018–2019 (group 2, 433 patients), respectively. We calculated CHA2DS2-VASc, HAS-BLED, and CCI and recorded the ACO decision and the use of VKA or NOAC in group 2. We compared the calculated scores between ACO and non-anticoagulated (nonACO) patients in both groups and between groups. Results. A 31.5% share of patients in group 1 and 12.9% in group 2 did not receive ACO despite a CHA2DS2-VASc score ≥ 2. In group 1, nonACO patients had higher HAS-BLED and CCI scores than the ACO patients, but their CHA2DS2-VASc scores were not significantly different. Old age, dementia, severe chronic kidney disease, neoplasia, and anemia were the most frequent reasons not to prescribe anticoagulants. In group 2, more nonACO patients had dementia, diabetes mellitus, and higher HAS-BLED than ACO patients. Moderate-severe CKD, neoplasia with metastasis, liver disease, anemia, and diabetes mellitus were statistically significantly more frequent in nonACO patients from group 1 than those from group 2. In group 2, 55.7% of ACO patients received NOAC. Conclusions. In real-world clinical practice, the decision for anticoagulation in NVAF is influenced by patient age, comorbidities, and risk of bleeding, and many patients do not receive anticoagulants despite a high CHA2DS2-VASc score. The use of NOAC in the past few years has improved treatment decisions. At the same time, the correct diagnosis, treatment, and surveillance of comorbidities have cut down the risk of bleeding and allowed anticoagulant use according to guidelines.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Siguret, V., and I. Gouin-Thibault. "Surveillance des traitements anticoagulants : dérivés hépariniques et antivitamine K." EMC - Biologie Médicale 7, no. 2 (June 2012): 1–11. http://dx.doi.org/10.1016/s2211-9698(12)56847-0.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Anticoagulant antivitamine K"

1

Attias, Nathalie. "Résistance au traitement par les antivitamines K." Paris 5, 1999. http://www.theses.fr/1999PA05P126.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

BERTHEOL, JACQUELINE LOUISE MARTINE. "Le relais heparine - antivitamine k peut-il etre standardise ? analyse prospective de la mise en place de 20 traitements anticoagulants." Clermont-Ferrand 1, 1993. http://www.theses.fr/1993CLF1M005.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

FONDO, JASKIEWICZ MARTINE. "Intoxications secondaires a l'ingestion de raticides anticoagulants." Reims, 1994. http://www.theses.fr/1994REIMM082.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Mahjoub, Tarek. "Etudes des propriétés toxicocinétiques et toxicodynamiques des anticoagulants antivitamines K et leurs impacts environnementaux chez les espèces animales non-cibles." Electronic Thesis or Diss., Lyon 1, 2023. https://n2t.net/ark:/47881/m6x34xkf.

Повний текст джерела
Анотація:
Les rodenticides anticoagulants (AR) constituent un moyen incontournable pour lutter contre les rongeurs nuisibles. L'utilisation écoresponsable des AR tend à limiter l'exposition des espèces non-cibles. Aucune étude sur la prévalence des AR chez les animaux n'a été menée en Tunisie. De ce fait, une première enquête toxicologique a montré que les AR sont incriminés parmi les causes les plus fréquentes d'intoxications aigues aux AR chez le chien. De plus, dans une autre étude, nous avons rapporté que les anticoagulants naturels, comme le férulénol produit par Ferula communis peut causer de lourdes pertes chez les éleveurs locaux. Peu d'études se sont intéressées à la toxicocinétique des AR. Pour évaluer la prévalence d'exposition, le choix de la matrice biologique est primordial et constitue un garant de la robustesse de la méthode utilisée. Le foie est le tissu de stockage des AR et constitue le meilleur prélèvement pour mettre en évidence une exposition chez les animaux. Cependant, ce prélèvement n'est disponible que sur les animaux morts. Par ailleurs, le sang et les fèces peuvent être utilisés sur des animaux vivants. Nous avons étudié la comparaison des trois matrices (foie, sang et fèces), en tenant compte de trois facteurs d'influence : la dose, le sexe et le temps. Nos résultats démontrent que les prélèvements fécaux sont plus utiles que les prélèvements plasmatiques pour le suivi de l'exposition aux AR des animaux domestiques et sauvages. Le tableau clinique lors d'une intoxication aigue aux AR est spectaculaire, cependant, les expositions à faibles doses passent inaperçues mais présentent des effets délétères insidieux sur la santé. L'exposition asymptomatique des animaux domestiques aux AR est peu documentée. Notre étude a montré une prévalence limitée chez les chiens et les chats, contrairement à d'autres travaux où la prévalence chez les prédateurs de la faune sauvage est bien supérieure et dont les analyses ont été réalisés sur les foies d'animaux morts de manière opportuniste, sans tenir compte des animaux sains. Ce travail pourrait générer des idées pour de nouvelles stratégies analytiques et permettrait de mieux aborder les particularités toxicocinétiques et toxicodynamiques chez d'autres espèces non-cibles dans le cadre du développement de nouvelles molécules d'AR plus écoresponsables
Anticoagulant rodenticides (AR) are an essential tool for controlling rodent pests. The environmentally responsible use of AR tends to limit the exposure of non-target species. No study on the prevalence of AR in animals has been conducted in Tunisia. Therefore, a first toxicological survey showed that AR are incriminated as one of the most frequent causes of acute AR poisoning in dogs. Moreover, in another study, we reported that natural anticoagulants, such as ferulenol produced by Ferula communis can cause heavy losses to local farmers. Few studies have focused on the toxicokinetics of AR. To monitor these exposure rates, the validation of the appropriate biological matrix is essential and is a major guarantee of the robustness of the analytical method. The liver is the storage tissue for AR and is the best sample for assessing exposure in animals. However, it is only available from dead animals. Blood and feces can be used from live animals. We studied the comparison of the three matrices (liver, blood, and feces), considering three influencing factors: dose, sex, and time. Our results show that fecal samples are more valuable than plasma samples for monitoring AR exposure in domestic and wild animals. The clinical symptoms of acute AR poisoning are dramatic, but low-dose exposures go unnoticed and present insidious deleterious health effects. Asymptomatic exposure of domestic animals to AR is poorly documented. Our study showed limited prevalence in dogs and cats, in contrast to other work where prevalence in wildlife predators is much higher from analyses performed on the livers of opportunistically dead animals, without considering the healthy ones. This work could generate ideas for new analytical strategies. It would allow better addressing toxicokinetic and toxicodynamic properties in other non-target species as part of the development of new, more eco-friendly AR molecules
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Brunie, Vanida. "Education thérapeutique des patients traités par anticoagulants oraux (AVK) : problématiques didactique et organisationnelle : Contribution à l’élaboration d’un modèle d’éducation thérapeutique." Thesis, Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCD093.

Повний текст джерела
Анотація:
Le traitement AVK concerne plus d’1% de la population française. Il représente un problème de santé publique majeur en raison de son importante iatrogénie. Les causes peuvent être notamment reliées à la complexité du parcours de soins des patients, à leurs erreurs, méconnaissances et incompréhensions. L’éducation thérapeutique (ETP) permettrait de contribuer à rendre ce patient autogestionnaire de ses propres risques. Cette recherche qualitative vise à proposer un modèle d’ETP en en identifiant les compétences d’auto-soins et d’adaptation à la maladie et en en précisant le programme, les méthodes pédagogiques et d’évaluation. Le protocole de recherche comporte une revue de la littérature sur les connaissances des patients, des entretiens de type semi-directifs de patients traités par AVK et de soignants-éducateurs, et enfin des entretiens avec un groupe d’experts. Trente-six entretiens associés à une revue extensive de la littérature ont permis d’élaborer un référentiel de huit compétences. Vingt-et-un objectifs pédagogiques découlent de ces compétences. Les principales difficultés des patients concernaient la mise en lien des concepts constitutifs du paradigme du traitement par AVK. Les huit compétences du référentiel correspondent à la gestion intelligible et sans danger d’un traitement anticoagulant. Les différents types de soignants-éducateurs envisagés pour ce modèle d’ETP se retrouvent dans le parcours de soins habituel des patients. Notre modèle pédagogique se veut applicable à différents contextes de soins. Les propositions tentent de répondre à la problématique de l’intelligibilité du traitement AVK et de rendre accessible aux patients l’éducation thérapeutique
The VKA treatment concerns more than 1% of the french population. It represents a major public health problem beacause of its consirable drug related iatrogny
Стилі APA, Harvard, Vancouver, ISO та ін.
6

PUGINIER, EMMANUEL ANDRE. "Vers une standardisation encore plus poussee du temps de quick pour surveiller le traitement anticoagulant oral : inr (international normalized ratio) et plasma calibre : a propos d'une etude toulousaine." Toulouse 3, 1988. http://www.theses.fr/1988TOU31249.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Pinède, Laurent. "Le traitement de la maladie thromboembolique veineuse des membres inférieurs : durée optimale de prescription des anticoagulants oraux : essai contrôlé multicentrique DOTAVK." Lyon 1, 2000. http://www.theses.fr/2000LYO1T010.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Machabert, Régine. "Le risque tératogène des antivitamines K : enquête auprès des centres de pharmacovigilance et revue de la littérature." Saint-Etienne, 1991. http://www.theses.fr/1991STET6223.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Bodin, Laurent. "Pharmacogénétique des anticoagulants oraux : variations génétiques du métabolisme et de la cible pharmacologique." Paris 5, 2005. http://www.theses.fr/2005PA05S026.

Повний текст джерела
Анотація:
Les antivitamines K (AVK) de type warfarine ou acenocoumarol (AC) sont les médicaments les plus largement prescrits en prévention et en traitement des troubles thromboemboliques. Il existe une grande variabilité interindividuelle dans la réponse thérapeutique ce qui peut conduire à un risque hémorragique. Le but de ce travail a été dans d'identifier les facteurs génétiques qui pouvait être lié à cette inter variabilité. Pour cela une dose unique d'acenocoumarol a été administrée à 222 volontaires sains chez lesquels l'effet pharmacologique a été mesuré par la variation du facteur VII et de l'INR au bout de 24 heures. Ainsi, deux polymorphismes génétiques, l'un sur le cytochrome P450 2C9 (CYP2C9), l'autre de la cible (la vitamine K epoxide reductase, VKORC1) permettent d'expliquer 50% de la variabilité de la réponse
Several publications brought to light the crucial impact of CYP2C9 and more recently VKORC1 genotypes to predict dose anticoagulant requirement and thus to prevent frequent complications (including bleeding). We reported that CYP2C9 and VKORC1 genetic variations account for 50% of the drug response variability after acenocoumarol intake and showed that haplotypic study of VKORC1 was not more informative than a single SNP, corresponding to the –1639G>A promoter variation. New dosing algorithms should incorporate a single SNP (–1639G>A) and be assessed rapidly in prospective studies to help clinical settings to individualize of warfarin dose. It would be of high interest for physicians to predict about 50% of the inter-individual variability of the coumarin response by the genotyping of two SNPs, CYP2C9*3 and –1639 G>A on the VKORC1 gene
Стилі APA, Harvard, Vancouver, ISO та ін.
10

CHANCE, THIERRY. "Interet et limites de l'international normalized ratio (inr) dans la surveillance biologique des traitements aux anticoagulants." Amiens, 1988. http://www.theses.fr/1988AMIEM141.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Anticoagulant antivitamine K"

1

Chevallier, Laurent. "Antivitamine K – Patients traités par anticoagulant." In 65 Ordonnances Alimentaires, 39–44. Elsevier, 2021. http://dx.doi.org/10.1016/b978-2-294-76804-0.00006-4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Anticoagulant antivitamine K"

1

Poort, S. R., C. Krommenhoek-van Es, I. K. van der Linden, N. H. van Tilburg, and R. M. Bertina. "DEFECTS OF VITAMIN K-DEPENDENT FACTORS IN CA(11)-STABILI ZED STRUCTURE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644320.

Повний текст джерела
Анотація:
Vitamin K-dependent (anti)coagulation factors (factor II, VII, IX, X protein C and S) undergo a conformational transition upon binding of Ca(II), which is a prerequisite for their normal function. Abnormalities in these properties occur during vitamin K deficiency or treatment with anti vitamin K drugs and in some genetic variants of coagulation factors. Immunological assays utilizing antibodies against the Ca(II)-stabilized structure are useful to detect such abnormalities.Starting from specific rabbit antisera antibody populations specific for the Ca(II)-dependent conformation of factor II, VII, IX, X and protein C and S were isolated using immuno-affinity procedures. Subsequently immunoradiometric assays specific for the Ca(II)-dependent (Ca(II)Ag) and Ca(II)-independent (NonCa(II)Ag) conformations of the different proteins were developed. These assays were used for the analysis of plasmas of patients stably treated with oral anticoagulants; Ca(II)Ag, NonCa(II)Ag and their ratio were measured as function of the intensity of the treatment (INR 2.4 to 4.8). The same parameters were measured in plasmas of patients with hereditary coagulation disorders. After treatment with oral anticoagulation with an antivitamin K drug reduced ratios of Ca(II)Ag/-NonCa(II)Ag were observed for factor II, VII, IX, protein C and protein S. However, the actual degree of reduction and its dependence on the intensity of treatment varied for the different vitamin K-dependent proteins. In general Ca(II)Ag levels correspond nicely with the procoagulant activity of the concerning proteins. These data provide indirect evidence for the existence of abnormal (non and/or subcarboxylated) forms of the vitamin K-dependent proteins during oral anticoagulant treatment.Genetic variants with a mutation in one of the sites involved in the formation of the Ca(II)-s tab i1ized structure could be detected for factor IX, factor VII and factor II. However, the extent of reduction of the ratio Ca(II)Ag/-NonCa(II)Ag differed considerably in those variants.
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Anticoagulant antivitamine K" для конкретних типів джерел:
Статті в журналах Дисертації
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії